Back to results

Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B

Primary Purpose

Influenza

Status

Suspended

Phase

Phase 3

Locations

United States

Study Type

Interventional

Intervention

fluID Rapid Influenza Test

BinaxNOW® Influenza A & B

About this trial

This is an interventional diagnostic trial for Influenza

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Male or female subjects of any age;
Subjects presenting to the investigative site within 4 days of symptom onset, with:
- Fever ≥ 38.0°C (100.4°F) if taken orally, or ≥ 38.5°C (101.2°F) if taken rectally; or a self-reported history of fever or feeling feverish (includes fever controlled by medication) in the absence of documented fever;
- One or more respiratory symptoms of influenza-like illness which may include the following:
- Sore throat
- Runny or stuffy nose
- Cough
- One or more constitutional symptoms of influenza-like illness which may include the following:
- Myalgia (aches and pains)
- Headache
- Fatigue
Subjects (or parent/guardian) willing and able to provide informed consent;
Subjects must be enrolled in Arm 3 of the FLU-05 clinical study.

Written subject informed consent for this study protocol must be obtained prior to study enrollment. Each subject (or parent or guardian) must personally sign and date the Subject Informed Consent Form prior to his/her participation in this clinical study.

Exclusion Criteria:

Subjects not presenting with at least three symptoms of influenza-like illness as outlined above.
Subjects who have received influenza antiviral medication or an investigational influenza drug treatment within the previous 30 days of study enrollment.
Subjects (children and adults) for whom the obtaining of aspirate samples is contraindicated or not possible.
Subjects with a medical condition that prevents nasal washes or aspirate samples from being obtained.
Active duty military personnel (participating military study sites only).
Subjects (or parent/guardian) unwilling or unable to provide informed consent.

Sites / Locations

Louisiana State University Health Sciences Center
Medical College of Wisconsin

Outcomes

Primary Outcome Measures

Positive percent agreement and negative percent agreement for both influenza A and influenza B.

Secondary Outcome Measures

Full Information

NCT ID

NCT00828100

First Posted

January 20, 2009

Last Updated

March 5, 2009

Sponsor

Nanogen, Inc.

1. Study Identification

Unique Protocol Identification Number

NCT00828100

Brief Title

Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B

Official Title

Comparison of fluID Rapid Influenza and BinaxNOW® Influenza A & B

Study Type

Interventional

2. Study Status

Record Verification Date

March 2009

Overall Recruitment Status

Suspended

Why Stopped

Study currently suspended due to a lack of available funding.

Study Start Date

February 2009 (undefined)

Primary Completion Date

May 2009 (Anticipated)

Study Completion Date

undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor

Nanogen, Inc.

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

The primary objective of this study is to compare the performance of the investigational fluid Rapid Influenza Test and the BinaxNOW® Influenza A & B Test in detecting influenza type A and influenza type B.

Detailed Description

The primary objective of this study is to compare the performance of the investigational fluID Rapid Influenza Test and the BinaxNOW® Influenza A & B Test in detecting influenza type A and influenza type B, with respect to fresh nasal wash / aspirate specimens collected from patients presenting with signs and symptoms of influenza-like illness (ILI). Specimens to be evaluated in this study will be enrolled in a concurrent clinical study per protocol FLU-05, entitled "Prospective Evaluation of the fluID Rapid Influenza Test". All subjects enrolled in the FLU-05 study will have consented to having their samples used in future investigations involving the fluID Test. This study will be conducted during the 2008-2009 influenza season in North America and Hong Kong, which is anticipated to run from November 2008 to May 2009. Should the influenza season conclude in North America and Hong Kong prior to the attainment of the minimum target enrollment specified in the FLU-05 study, study sites in Australia will also be enlisted in order to enroll subjects; in such a case, enrollment will continue during the 2009 influenza season in these countries, which is anticipated to run from May through October, 2009.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Influenza

7. Study Design

Primary Purpose

Diagnostic

Study Phase

Phase 3

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

650 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type

Device

Intervention Name(s)

fluID Rapid Influenza Test

Intervention Description

The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.

Intervention Type

Device

Intervention Name(s)

BinaxNOW® Influenza A & B

Intervention Description

The BinaxNOW Influenza A & B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.

Primary Outcome Measure Information:

Title

Positive percent agreement and negative percent agreement for both influenza A and influenza B.

Time Frame

End of study

10. Eligibility

Sex

All

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Male or female subjects of any age; Subjects presenting to the investigative site within 4 days of symptom onset, with: Fever ≥ 38.0°C (100.4°F) if taken orally, or ≥ 38.5°C (101.2°F) if taken rectally; or a self-reported history of fever or feeling feverish (includes fever controlled by medication) in the absence of documented fever; One or more respiratory symptoms of influenza-like illness which may include the following: Sore throat Runny or stuffy nose Cough One or more constitutional symptoms of influenza-like illness which may include the following: Myalgia (aches and pains) Headache Fatigue Subjects (or parent/guardian) willing and able to provide informed consent; Subjects must be enrolled in Arm 3 of the FLU-05 clinical study. Written subject informed consent for this study protocol must be obtained prior to study enrollment. Each subject (or parent or guardian) must personally sign and date the Subject Informed Consent Form prior to his/her participation in this clinical study. Exclusion Criteria: Subjects not presenting with at least three symptoms of influenza-like illness as outlined above. Subjects who have received influenza antiviral medication or an investigational influenza drug treatment within the previous 30 days of study enrollment. Subjects (children and adults) for whom the obtaining of aspirate samples is contraindicated or not possible. Subjects with a medical condition that prevents nasal washes or aspirate samples from being obtained. Active duty military personnel (participating military study sites only). Subjects (or parent/guardian) unwilling or unable to provide informed consent.

Facility Information:

Facility Name

Louisiana State University Health Sciences Center

City

Shreveport

State/Province

Louisiana

ZIP/Postal Code

71103

Country

United States

Facility Name

Medical College of Wisconsin

City

Milwaukee

State/Province

Wisconsin

ZIP/Postal Code

53226

Country

United States

12. IPD Sharing Statement

Learn more about this trial

Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B

We'll reach out to this number within 24 hrs